97058 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
Compositions and methods for increasing serum half-life
#302Chimeric Receptors and Methods for Identifying Agents Exhibiting an Activity on Type 1 Single Pass Transmembrane Receptors
#303ALBUMIN FUSION PROTEINS
#304Dual antagonist for TNF-α and IL-21 for preventing and treating autoimmune diseases
#305WAP domain fusion polypeptides and methods of use thereof
#306Serpin fusion polypeptides and methods of use thereof
#307Use of Low Affinity Neurotrophin Receptor P75 As Marker for High Differentiation Potential Muscle Stem Cells, Muscle Satellite Cells, And Degenerative Skeletal Muscle Diseases
#308Method of preventing acute or sub-acute hepatic failure by administering a long-acting recombinant human soluble tumor necrosis factor alpha receptor II fusion protein
#309Transgenic pig in which HO-1 and TNFR1-Fc are simultaneously expressed, and method for producing same
#310Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
#311ALBUMIN FUSION PROTEINS
#312Method for producing proteins in that lack detectable cross binding activity to antibodies against host cell antigens
#313Agent and methods for reducing inflammatory markers
#314Methods of screening for a compound that inhibits the interaction between BAFF and BCMA
#315Receptor activator of NF-kappaB
#316Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
#317SOLUBLE THF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
#318Albumin fusion proteins
#319Albumin Fusion Proteins
#320Method for in vivo expansion of T regulatory cells
#321Cofilin knockdown host cells and uses thereof
#322Fc variants with altered binding to FcRn
#323Method for inhibiting BAFF-R activity
#324Albumin fusion proteins
#325Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#326Cells and methods for producing blocking antibodies to human RANKL
#327Antibody for Targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1
#328B-LYMPHOCYTE STIMULATOR BINDING POLYPEPTIDES AND METHODS BASED THEREON
#329METHODS AND COMPOSITIONS TO REDUCE LIVER DAMAGE ASSOCIATED WITH CONDITIONS OR THERAPIES THAT AFFECT THE IMMUNE SYSTEM
#330Method of treating immunological disorders by administering truncated BAFF receptors
#331Albumin Fusion Proteins
#332Cytokines and Cytokine Receptors with Reduced Immunogenicity
#333Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders
#334Expression vector and methods of producing high levels of proteins
#335Kits for detecting rank
#336REGULATION OF LYMPHOCYTES AND USES THEREFOR
#337Alteration of Fc-fusion protein serum half-lives by mutagenesis
#338TGF-Beta Antagonist Multi-Target Binding Proteins
#339Compositions and methods for increasing serum half-life
#340Train-R: A Cysteine Rich Member of the TNF-Receptor Family
#341TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS
#342PURIFIED IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF THEIR PURIFICATION
#343Chimeric proteins and uses thereof
#344Soluble tumor necrosis factor receptor mutant
#345Fc variants with altered binding to FcRn
#346SOLUBLE TNF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
#347Small molecular weight TNF receptor multimeric molecule
#348Combinatorial Libraries Based on C-type Lectin-like Domain
#349Method of inhibiting osteoclast activity
#350Methods of identifying compounds that bind TANGO509
#351Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling
#352Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells
#353Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells
#354Human Tumor Necrosis Factor TR18 and Methods Based Thereon
#355Albumin fusion proteins
#356Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof
#357Method of identifying compounds that bind BAFF-R
#358Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#359Compositions and methods for tissue repair
#360Polynucleotides encoding concatameric immunoadhesion molecules
#361Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells
#362Peptides and related molecules that bind to TALL-1
#363ErbB interface peptidomimetics and methods of use thereof
#364FC VARIANTS WITH ALTERED BINDING TO FCRN
#365Fc variants with altered binding to FcRn
#366Fc variants with altered binding to FcRn
#367Fc variants with altered binding to FcRn
#368FC variants with altered binding to FCRN
#369Process for isolation and purification of a target protein free of prion protein (PrP)
#370Fc variants with altered binding to FcRn
#371Protein Layers And Their Use In Electron Microscopy
#372ANTIBODIES TO HUMAN TUMOR NECROSIS FACTOR RECEPTOR
#373Albumin Fusion Proteins
#374MONOCLONAL ANTIBODIES TO ACTIVATED ERBB FAMILY MEMBERS AND METHODS OF USE
#375Truncated BAFF receptors
#376Use of Tumor Necrosis Factor-Alpha P75 Receptor for the Reduction of Inflammation
#377B-lymphocyte stimulator binding polypeptides and methods based thereon
#378Method for the high level expression of active tumor necrosis receptor family member immunoglobulin fusion proteins
#379ErbB interface peptidomimetics and methods of use thereof
#380ErbB interface peptidomimetics and methods of use thereof
#381Amelioration of Inflammatory Arthritis By Targeting the Pre-ligand Assembly Domain (Plad) of Tumor Necrosis Factor Receptors
#382BAFF RECEPTOR (BCMA), AN IMMUNOREGULATORY AGENT
#383TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF
#384Methods of identifying agents that selectively activate p38 and/or NKkB signaling
#385ErbB interface peptidomimetics and methods of use thereof
#386Albumin Fusion Proteins
#387Purified TNFR preparations
#388Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
#389Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with tumor necrosis factor antagonists
#390Cytokines and Cytokine Receptors With Reduced Immunocencity
#391Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells
#392Human Endokine Alpha and Methods of Use
#393Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells
#394Tumor necrosis factor receptors 6α and 6β
#395Method of preventing acute or sub-acute hepatic failure in a subject by administering a soluble human tumor necrosis factor alpha fusion protein
#396Fc variants with altered binding to FcRn
#397TNF antagonists
#398Methods of inhibiting proliferation or immunoglobulin production of B cells using human tumor necrosis factor receptor TR-17 polypeptides
#399Methods of determining the level of human tumor necrosis factor receptor-like 2
#400Albumin Fusion Proteins
#401Albumin Fusion Proteins
#402Albumin Fusion Proteins
#403Anti-p55 TNF receptor antibody
#404Albumin Fusion Proteins
#405Methods for interfering with rank signaling
#406Concatameric immunoadhesion molecule
#407Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor
#408Multimers of Peptides
#409Chimeric Protein
#410Alteration of Fc-fusion protein serum half-lives by mutagenesis
#411Chimeric proteins, their preparation and pharmaceutical compositions containing them
#412Albumin Fusion Proteins
#413Albumin Fusion Proteins
#414Albumin Fusion Proteins
#415Albumin fusion proteins
#416Albumin Fusion Proteins
#417Albumin Fusion Proteins
#418Composition and method for modulating an inflammatory response
#419Fused Protein Composition
#420Human Tumor Necrosis Factor TR18 and Methods Based Thereon
#421Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases
#422Albumin fusion proteins
#423Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
#424Genetically engineered and phenotyped mice and stem cell clones for producing the same
#425Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist
#426Albumin Fusion Proteins
#427Albumin fusion proteins comprising insulin polypeptides
#428Albumin Fusion Proteins
#429G-CSF-albumin fusion proteins
#430Albumin fusion proteins
#431Albumin fusion proteins
#432Method for producing recombinant proteins
#433METHODS OF INCREASING PROTEIN EXPRESSION LEVELS
#434Kits for detecting rank nucleic acids
#435Novel receptor that causes cell death
#436Human tumor necrosis factor receptor TR9 antibody
#437ZTNFR14, A Tumor Necrosis Factor Receptor
#438Binding polypeptides and methods based thereon
#439Albumin fusion proteins
#440Human tumor necrosis factor receptor
#441Albumin fusion proteins
#442Soluble TNF receptors and their use in treatment of disease
#443Albumin fusion proteins
#444Antibodies to tumor necrosis factor receptor associated factor polypeptides
#445MODULATOR OF TNF/NGF SUPERFAMILY RECEPTORS AND SOLUBLE OLIGOMERIC TNF/NGF SUPERFAMILY RECEPTORS
#446Inhibitors of pre-ligand assembly doman and function of the tumor necrosis factor receptor family
#447Mammalian cell culture process
#448Cell death modulation via antagonists of Fasl and Fas activation
#449Human tumor necrosis factor receptor polynucleotides
#450Modulators of regulatory proteins
#451Modulators of the function of FAS receptors and other proteins
#452Biological agent that causes IL-6 receptor release
#453Leader sequences for use in production of proteins
#454Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
#455Methods for blocking TNF-alpha activity in mammals with trimeric soluble TNF receptors
#456Process for the production of tumor necrosis factor-binding proteins
#457Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
#458Chimeric polypeptide and use thereof
#459HUMAN TUMOR NECROSIS FACTOR RECEPTOR POLYPEPTIDES
#460HUMAN TUMOR NECROSIS FACTOR RECEPTOR
#461ANTIBODIES TO HUMAN TUMOR NECROSIS FACTOR RECEPTOR
#462Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
#463Site specific protein modification
#464Tumor necrosis factor alpha
#465Small molecular weight TNF receptor multimeric molecule
#466Novel protein related to melanoma-inhibiting protein and uses thereof
#467Erythropoietin: remodeling and glycoconjugation of erythropoietin
#468Antibody to TNF receptor-like molecules
#469Methods for purifying protein
#470Trimeric binding proteins for trimeric cytokines
#471Methods of inhibiting an immune response with anti-human endokine alpha antibodies
#472Remodeling and glycoconjugation of peptides
#473Cell surface receptor isoforms and methods of identifying and using the same
#474Albumin fusion proteins
#475Fusion proteins comprising tumor necrosis factor receptor
#476Methods of monitoring treatment of BAFF-R related disease
#477NOVEL RECEPTOR NUCLEIC ACIDS AND POLYPEPTIDES
#478BAFF receptor polypeptides
#479BAFF receptor antibodies and methods
#480Truncated baff receptors
#481Tumor Necrosis Factor Receptors 6 Alpha & 6 Beta
#482TRAIN-R: a cysteine-rich member of the TNF-receptor family
#483Human tango 509 polypeptides
#484TNF receptor action modulation
#485Albumin fusion proteins
#486Antibodies to tumor necrosis factor receptors 6α and 6β
#487DADD, death activator death domain protein
#488Secreted proteins and nucleic acids encoding them
#489Peptides and related molecules that bind to TALL-1
#490Ubiquitinated TNF receptor2 and its uses
#491Process for the purification of tnf-binding proteins using imac
#492Production of TNFR-Ig
#493Binding polypeptides and methods based thereon
#494Methods and reagents relating to inflammation and apoptosis
#495Monoclonal antibodies to activated erbB family members and methods of use thereof
#496Glycoproteins which bind to TNF
#497Methods of treatment using human tumor necrosis factor receptor TR17 antibodies
#498Methods of treatment with TR10 polypeptides
#499Albumin fusion proteins
#500Albumin fusion proteins
#501Ztnfr14, a tumor necrosis factor receptor
#502Ztnf12, a tumor necrosis factor
#503Nucleic acids encoding truncated soluble tumor necrosis factor
#504DNA encoding tumor necrosis factor inhibitory protein and its use
#505Albumin fusion proteins
#506Human tumor necrosis factor receptors TR13 and TR14
#507Human tumor necrosis receptor TR9
#508Alteration of Fc-fusion protein serum half-lives by mutagenesis
#509Tumor necrosis factor super family agonists
#510Cytokines and cytokine receptors with reduced immunogenicity
#511Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
#512Albumin fusion proteins comprising GLP-1 polypeptides
#513Death domain containing receptor 4 antibodies and methods
#514Pharmaceutical compositions of glycoconjugates
#515Albumin fusion proteins
#516Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
#517Human tumor necrosis factor receptors TR21 and TR22
#518Methods of increasing protein expression levels
#519Taci and br3 polypeptides and uses thereof
#520Antibodies that specifically bind to TR2
#521Inhibitors of apoptosis
#522Methods for inhibiting lymphotoxin β receptor signalling
#523Crystals of etanercept and methods of making thereof
#524Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses
#525Monoclonal blocking antibody to human RANKL
#526N-TRADD active site and uses thereof